Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Return on Equity (2017 - 2025)

Lexaria Bioscience's Return on Equity history spans 9 years, with the latest figure at 2.86% for Q4 2025.

  • For Q4 2025, Return on Equity fell 201.0% year-over-year to 2.86%; the TTM value through Nov 2025 reached 2.86%, down 201.0%, while the annual FY2025 figure was 2.23%, 112.0% down from the prior year.
  • Return on Equity for Q4 2025 was 2.86% at Lexaria Bioscience, down from 2.78% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.0% in Q3 2021 and bottomed at 2.86% in Q4 2025.
  • The 5-year median for Return on Equity is 0.89% (2022), against an average of 1.04%.
  • The largest annual shift saw Return on Equity soared 112bps in 2024 before it crashed -212bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.17% in 2021, then tumbled by -463bps to 0.93% in 2022, then crashed by -112bps to 1.97% in 2023, then soared by 57bps to 0.86% in 2024, then plummeted by -235bps to 2.86% in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Return on Equity are 2.86% (Q4 2025), 2.78% (Q3 2025), and 1.85% (Q2 2025).